0% found this document useful (0 votes)
6 views15 pages

Tykerb: Mechanism and Efficacy in HER2+ Cancer

The document discusses the cellular mechanism of action of Tykerb. It states that HER2 is a tyrosine kinase receptor that plays critical roles in cell growth and differentiation signaling pathways. Amplification and overexpression of the HER2 oncogene results in uncontrolled cell proliferation and is seen in HER2-positive breast cancer. It further notes that Tykerb inhibits HER2 phosphorylation and subsequent downstream signaling.

Uploaded by

api-529605052
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
6 views15 pages

Tykerb: Mechanism and Efficacy in HER2+ Cancer

The document discusses the cellular mechanism of action of Tykerb. It states that HER2 is a tyrosine kinase receptor that plays critical roles in cell growth and differentiation signaling pathways. Amplification and overexpression of the HER2 oncogene results in uncontrolled cell proliferation and is seen in HER2-positive breast cancer. It further notes that Tykerb inhibits HER2 phosphorylation and subsequent downstream signaling.

Uploaded by

api-529605052
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd

Performance Task

Tykerb Assessment
Alex Raschiatore, Brady
Kesterholt.
Cellular Mechanism of action
● HER2 is a tyrosine kinase receptors in the class of erbB (Schroeder, R., Stevens, C., & Sridhar, J., 2014)

● Critical roles in the signal transduction cascade in pathways responsible for cell growth and differentiation
(Schroeder, R., Stevens, C., & Sridhar, J. , 2014)

● Amplification and overexpression of the HER2 encoding oncogene results in unregulated cell proliferation
(Schroeder, R., Stevens, C., & Sridhar, J. , 2014)
○ In an aggressive form of breast cancer known as HER2-positive breast cancer. (Schroeder, R., Stevens, C., &
Sridhar, J. , 2014)
Cellular Mechanism of action

(2019). Retrieved 14 November 2019, from [Link]


or-heterodimerization-with-other_fig1_259456792
Document A

❖ Credible

❖ Targeted drugs - Herceptin, Avastin, and Tykerb (Document A)

❖ Drug similar to Tykerb are Herceptin (Document A)

❖ Benefits of having similar drugs (Document A)


Document B

❖ Noncredible

❖ Breast examination (Document B)

❖ HER2 not effective by chemotherapy (Document B)

❖ Breast cancer in 1 out of 7 non hereditary link (Document B)


Document C

❖ Credible

❖ Trend of decreased stress (Document C)

❖ Over 8 Week treatment of Tykerb (Document C)

❖ Unlikely correlation between Tykerb and stress levels (Document C)


Document D
❖ Credible

❖ Drug combinations

❖ Higher response to tykerb with the other medication (Document D)


➢ Chemotherapy

❖ Clinic trial (Document D)


Document E

❖ Credible

❖ Tumor decrease with higher dosage (Document E)

❖ Around 40 % decrease in tumor size (Document E)

❖ 1250 mg of Tykerb with chemotherapy was most effective (Document E)


Document F
❖ Not Credible
➢ Biased

❖ Discusses the benefits of herbal medicine as an anti-cancer (Document F)


➢ More cost efficient than pharmaceutical drugs (Document F)
➢ Certain foods have chemopreventive benefits (Document F)

❖ Tykerb not relevant to article


Document G

❖ Credible
➢ Trial done in three phases (Document G)
➢ Results for drug effect prostate (Document G)

❖ Herbal interaction with anti cancer drug (Document G)

❖ No mention of Tykerb
Document H

❖ Ryan forbes
➢ founder of Natural Way (Document H)

❖ Does not support ineffectiveness or harmfulness of St. John Wort (Document H)

❖ Credible
➢ Reliable source of tykerb information
Strengths

❖ Decreased tumor size (Document E)

❖ Already approved by the FDA (Document A)

❖ Can be used in combination with other drugs (Document D)


Weaknesses

❖ Insurances most likely won't cover the cost (Document A)

❖ Drug usually reserved for women who are either allergic to other medications or who have already undergone
treatments with trastuzumab which have failed (Document A)

❖ Combination with chemotherapy to be effective (Document E)


Recommendations

★ Overall, we thought that Dr. Pill should continue their work with Tykerb because the drug overall was shown

to be a strong option itself. For the treatment of breast cancer in patients with an overexpression in the Her2

protein.
References
● Documents A-H

● Schroeder, R., Stevens, C., & Sridhar, J. (2014). Small molecule tyrosine kinase inhibitors of erbb2/her2/neu in the treatment of
aggressive breast cancer. Molecules (basel, Switzerland), 19(9), 15196-212. doi:10.3390/molecules190915196

● (2019). Retrieved 14 November 2019, from [Link]


homodimerization-or-heterodimerization-with-other_fig1_259456792

You might also like